ClinConnect ClinConnect Logo
Search / Trial NCT05552222

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Launched by JANSSEN RESEARCH & DEVELOPMENT, LLC · Sep 21, 2022

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying two combinations of medications for patients with newly diagnosed multiple myeloma, a type of blood cancer. The combinations being tested are teclistamab with daratumumab and lenalidomide (Tec-DR) and talquetamab with daratumumab and lenalidomide (Tal-DR). The goal is to see how well these combinations work compared to the standard treatment of daratumumab, lenalidomide, and dexamethasone (DRd).

To participate in this study, patients must be newly diagnosed with multiple myeloma and not eligible for high-dose chemotherapy with stem cell transplant due to age or other health conditions. They should also be between the ages of 65 and 74 and meet other criteria related to their health status. Participants can expect to receive one of the treatment combinations and will be monitored closely for effectiveness and side effects. It's important to note that women who are pregnant or breastfeeding, as well as men planning to father a child, will need to avoid participation due to safety concerns. This trial is currently recruiting participants, and it aims to find better treatment options for individuals facing this challenging condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
  • Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
  • A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment
  • Exclusion Criteria:
  • Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams \[mg\] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (\>=) 20 mg of dexamethasone within 14 days before randomization
  • Had plasmapheresis within 28 days of randomization
  • Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization
  • Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients
  • Known contraindications to the use of daratumumab or lenalidomide per local prescribing information
  • Myeloma Frailty Index of \>=2 with the exception of participants who have a score of 2 based on age alone

About Janssen Research & Development, Llc

Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, is a leading pharmaceutical company dedicated to advancing innovative therapies in multiple therapeutic areas, including oncology, immunology, neuroscience, infectious diseases, and cardiovascular health. With a strong commitment to scientific excellence and patient-centered research, Janssen leverages cutting-edge technology and collaborative partnerships to drive the development of transformative treatments. The company is focused on addressing unmet medical needs through rigorous clinical trials and a robust pipeline, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Durham, North Carolina, United States

Durham, North Carolina, United States

Boston, Massachusetts, United States

Saint Louis, Missouri, United States

Edmonton, Alberta, Canada

New York, New York, United States

Seattle, Washington, United States

Vejle, , Denmark

Washington, District Of Columbia, United States

Boston, Massachusetts, United States

Omaha, Nebraska, United States

Dallas, Texas, United States

Stony Brook, New York, United States

London, , United Kingdom

Portland, Oregon, United States

Rozzano, , Italy

Southfield, Michigan, United States

Woolloongabba, Queensland, Australia

Kortrijk, , Belgium

Ottawa, Ontario, Canada

Farmington, Connecticut, United States

Nedlands, , Australia

Porto Alegre, , Brazil

Houston, Texas, United States

Milan, , Italy

Nantes, , France

Yamanashi, , Japan

Trondheim, , Norway

Seoul, , Korea, Republic Of

Blackpool, , United Kingdom

Turku, , Finland

Tucson, Arizona, United States

Stockholm, , Sweden

Edinburgh, , United Kingdom

Oulu, , Finland

Louisville, Kentucky, United States

New York, New York, United States

Ramat Gan, , Israel

Cambridge, Cambridgeshire, United Kingdom

Wolverhampton, , United Kingdom

Vienna, , Austria

Beijing, Beijing, China

Seoul, , Korea, Republic Of

Gothenburg, , Sweden

New Delhi, , India

Santa Fe, New Mexico, United States

Aalborg, , Denmark

Leeds, , United Kingdom

New Haven, Connecticut, United States

Camperdown, , Australia

Woolloongabba, , Australia

Gent, , Belgium

Firenze, , Italy

Dijon, , France

Busan, , Korea, Republic Of

Falun, , Sweden

Stockholm, , Sweden

Seoul, , Korea, Republic Of

Cambridge, , United Kingdom

Nantes, , France

Hirakata, , Japan

Salamanca, , Spain

Duarte, California, United States

Durham, North Carolina, United States

Allentown, Pennsylvania, United States

Kanagawa, , Japan

Beijing, , China

Budapest, , Hungary

New Brunswick, New Jersey, United States

Charlotte, North Carolina, United States

Okayama, , Japan

Bern, , Switzerland

Cleveland, Ohio, United States

Wollongong, , Australia

Leuven, , Belgium

Hradec Kralove, , Czechia

Lublin, , Poland

Harbin, , China

Jerusalem, , Israel

Goyang Si, , Korea, Republic Of

Incheon, , Korea, Republic Of

Liverpool, , Australia

Hwasun, , Korea, Republic Of

Brno, , Czechia

Mainz, , Germany

Budapest, , Hungary

Nuernberg, , Germany

örebro, , Sweden

Daegu, , Korea, Republic Of

Beijing, Beijing, China

Ostrava, , Czechia

Shenyang, Liaoning, China

Nieuwegein, , Netherlands

Fort Belvoir, Virginia, United States

Kanazawa, , Japan

Zhengzhou, Henan, China

Tianjin, , China

Jinan, Shandong, China

Nanjing, , China

Lille, , France

Hamilton, Ontario, Canada

Hwasun, , Korea, Republic Of

Omaha, Nebraska, United States

Helsinki, , Finland

Anderlecht, , Belgium

Chengdu, , China

Dortmund, , Germany

Delft, , Netherlands

Pierre Benite, , France

Shanghai, , China

Haifa, , Israel

Amsterdam, , Netherlands

Pessac Cedex, , France

Istanbul, , Turkey

Canterbury, , United Kingdom

Vancouver, British Columbia, Canada

Wien, , Austria

Busan, , Korea, Republic Of

Murdoch, , Australia

Salzburg, , Austria

Brzozow, , Poland

Thessalonikis, , Greece

Sapporo Shi, , Japan

Bunkyo Ku, , Japan

Xiamen, , China

Higashiibaraki Gun, , Japan

London, , United Kingdom

Katowice, , Poland

Natal, , Brazil

Olomouc, , Czechia

St. Gallen, , Switzerland

Zhengzhou, , China

Beijing, , China

Creteil, , France

Changchun, Jilin, China

Sittard Geleen, , Netherlands

Augusta, Georgia, United States

Izmir, , Turkey

Würzburg, , Germany

Wilrijk, , Belgium

Toulouse, , France

Chandigarh, , India

Madrid, , Spain

Valencia, , Spain

Sao Paulo, , Brazil

Porto, , Portugal

Poitiers, , France

Seoul, , Korea, Republic Of

Lund, , Sweden

Madrid, , Spain

Katowice, , Poland

Seoul, , Korea, Republic Of

Badalona, , Spain

Bombay, , India

Barcelona, , Spain

Madrid, , Spain

Osaka, , Japan

Olomouc, Olomoucký Kraj, Czechia

Toyoake, , Japan

Plzen, , Czechia

Sunto Gun, , Japan

Rennes, , France

Matsuyama City, , Japan

Roskilde, , Denmark

Bangalore, , India

Shanghai, , China

Zürich, , Switzerland

Linz, , Austria

Pune, , India

Iruma Gun, , Japan

Guangzhou, , China

Sao Paulo, , Brazil

Palma De Mallorca, , Spain

Pondicherry, , India

São Paulo, , Brazil

Wenzhou, , China

Tübingen, , Germany

Budapest, , Hungary

Olomouc, , Czechia

Athens Attica, , Greece

Shibukawa, , Japan

Bydgoszcz, , Poland

Granada, , Spain

Pozuelo De Alarcon, , Spain

Salvador, , Brazil

Calgary, Alberta, Canada

Berlin, , Germany

Apeldoorn, , Netherlands

Oslo, , Norway

Torino, , Italy

Bern, , Switzerland

Nagasaki, , Japan

Terrassa, , Spain

Geelong, , Australia

Nanchang, , China

Pécs, , Hungary

Sapporo, , Japan

Lisbon, , Portugal

Birmingham, , United Kingdom

Shreveport, Louisiana, United States

Haine Saint Paul, La Louviere, , Belgium

Jaipur, , India

Antalya, , Turkey

Quebec, , Canada

Chongqing, Chongqing, China

Ankara, , Turkey

Kielce, , Poland

Krakow, , Poland

Rennes, , France

Jerez De La Frontera, , Spain

Nagpur, , India

Almada, , Portugal

Braga, , Portugal

Bristol, , United Kingdom

St. Gallen, , Switzerland

örebro, , Sweden

Thessaloniki, , Greece

Roma, , Italy

Sittard, , Netherlands

Torino, , Italy

Changsha, , China

Pavia, , Italy

Istanbul, , Turkey

Detroit, Michigan, United States

Bologna, , Italy

Kolkata, , India

Herning, , Denmark

Hamburg, , Germany

Guangzhou, , China

Shibuya Ku, , Japan

Niteroi, , Brazil

Hangzhou, , China

Hyôgo, , Japan

Wurzburg, , Germany

Shenyang, , China

Ankara, , Turkey

Seoul, , Korea, Republic Of

La Jolla, California, United States

Camden, New Jersey, United States

New South Wales, , Australia

Linz, , Austria

Belo Horizonte, Minas Gerais, , Brazil

Fortaleza, , Brazil

Ribeirao Preto, , Brazil

Fu Zhou, , China

Hang Zhou, , China

Tian Jin, , China

Xi' An, , China

Praha, , Czechia

Paris Cedex 12, , France

Gurugram, , India

Naples, , Italy

Olsztyn, , Poland

Samsun, , Turkey

London, , United Kingdom

Irvine, California, United States

Bunkyo Ku, , Japan

Chiba, , Japan

Kumamoto Shi, , Japan

Barretos, , Brazil

Ribeirão Preto, , Brazil

Ribeirao Preto, , Brazil

Pessac Cedex, , France

Curitiba, , Brazil

Ribeirao Preto, , Brazil

Yamagata, , Japan

Sao Paulo, , Brazil

Poznan, , Poland

Weston, Florida, United States

Herning, , Denmark

Chaoyang District, , China

Brno Bohunice, , Czechia

Oslo, , Norway

Goyang Si, , Korea, Republic Of

Strasbourg, , France

Niteroi, , Brazil

Brzozow, , Poland

Thessalonikis, , Greece

Ankara, , Turkey

Chengdu, , China

Bologna, , Italy

Osaka, , Japan

Thessaloniki, , Greece

Ribeirao Preto, , Brazil

Bergamo, , Italy

Bunkyo Ku, , Japan

Tel Aviv Yafo, , Israel

Poitiers, , France

Shanghai, , China

Tian Jin, , China

Grand Rapids, Michigan, United States

Quebec, , Canada

Shanghai, , China

Lodz, , Poland

Halle (Saale), , Germany

Sao Paulo, , Brazil

Seoul, , Korea, Republic Of

Salamanca, , Spain

Calgary, Alberta, Canada

Haine Saint Paul La Louviere, , Belgium

Guangzhou, , China

Wuhan, , China

Paris Cedex 12, , France

Petah Tikva, , Israel

Roma, , Italy

Porto, , Portugal

Barcelona, , Spain

Madrid, , Spain

Salzburg, , Austria

Belo Horizonte, , Brazil

Chiba, , Japan

Porto, , Portugal

Denizli, , Turkey

Curitiba, , Brazil

Katowice, , Poland

Sao Paulo, , Brazil

Chang Zhou, , China

Nan Jing, , China

Nan Ning Shi, , China

Chiba, , Japan

Des Moines, Iowa, United States

Barretos, , Brazil

Hirakata, , Japan

Shen Zhen Shi, , China

Zielona Gora, , Poland

Porto, , Portugal

Braga, , Portugal

Porto Alegre, , Brazil

Hang Zhou, , China

Calgary, Alberta, Canada

Kanazawa, , Japan

Biala Podlaska, , Poland

Calgary, Alberta, Canada

Sunto Gun, , Japan

Kielce, , Poland

Lublin, , Poland

Beijing, , China

Yamagata, , Japan

Antwerpen, , Belgium

Waukee, Iowa, United States

Patients applied

0 patients applied

Trial Officials

Janssen Research & Development, LLC Clinical Trial

Study Director

Janssen Research & Development, LLC

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials